Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of "Hold" by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have been given an average rating of "Hold" by the twenty-one analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $111.53.

ZBH has been the topic of a number of research reports. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. The Goldman Sachs Group dropped their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Royal Bank Of Canada reduced their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, Truist Financial set a $101.00 price objective on Zimmer Biomet in a research report on Tuesday, May 6th.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider now owns 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.39% of the company's stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors have recently modified their holdings of ZBH. AG2R LA Mondiale Gestion D Actifs bought a new position in Zimmer Biomet during the first quarter worth $1,179,000. Strs Ohio bought a new position in Zimmer Biomet during the first quarter worth $35,652,000. Mattson Financial Services LLC increased its position in Zimmer Biomet by 9.0% during the first quarter. Mattson Financial Services LLC now owns 19,636 shares of the medical equipment provider's stock worth $2,222,000 after acquiring an additional 1,616 shares during the period. Focus Partners Wealth increased its position in Zimmer Biomet by 2.6% during the first quarter. Focus Partners Wealth now owns 16,955 shares of the medical equipment provider's stock worth $1,919,000 after acquiring an additional 427 shares during the period. Finally, Flaharty Asset Management LLC bought a new position in Zimmer Biomet during the first quarter worth $94,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

NYSE ZBH opened at $91.46 on Friday. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet has a 1 year low of $89.22 and a 1 year high of $116.71. The company has a market cap of $18.10 billion, a PE ratio of 20.23, a PEG ratio of 2.11 and a beta of 0.72. The stock's 50-day moving average price is $94.65 and its two-hundred day moving average price is $102.23.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same period in the prior year, the firm earned $1.94 earnings per share. The business's quarterly revenue was up 1.1% on a year-over-year basis. On average, analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's payout ratio is presently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.